Porton Biopharma

The company is expert at taking concepts from the research laboratory, progressing them through various stages of scale-up and process development to production of material suitable for clinical trial and licensure.

biopharmaceutical therapeutics and vaccines

Porton Biopharma's strategy as a new company with a distinguished heritage is to grow our existing business, develop our product pipeline and build relationships across the industry.

Our state-of-the-art cGMP manufacturing facilities are licensed by the MHRA and FDA. We manufacture our own biopharmaceutical products, which include the UK's licensed anthrax vaccine, and the therapeutic enzyme Erwinase, which is used to treat acute lymphoblastic leukaemia (ALL) and is distributed in up to 80 countries worldwide.

We offer

PBL offers expertise in the developmental production of biologicals, including product characterisation, process and analytical validation, and scalability for market. Allied with our experience of regulatory compliance gained from the licensure of our own products, this puts it in an ideal position to offer expertise and enable our customers to successfully bring their products to market.

About us

We were commercialised out of Public Health England on 1 April 2015 to enable us to be better placed to grow our business. The company is built upon decades of biopharmaceutical experience, including the successful licensure of many therapies that now save thousands of lives every year and generate revenues from worldwide sales.